BSE: 530239 | NSE: SUVEN | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Suven Life Sciences Ltd is a average quality company.
The key valuation ratios of Suven Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Suven Life Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 30.7% | 19.2% | 21.9% | 27.6% | 10% | -6.4% | -6.8% | -8.1% | -3% | -1% | - |
| Value Creation Index ⓘ | 1.2 | 0.4 | 0.6 | 1.0 | -0.3 | -1.5 | -1.5 | -1.6 | -1.2 | -1.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 521 | 500 | 544 | 625 | 286 | 14.4 | 13.5 | 11.8 | 13.5 | 11.7 | 8 |
| Sales YoY Gr. | - | -4.1% | 8.8% | 15% | -54.3% | -95% | -6.5% | -12.2% | 14.4% | -13.7% | - |
| Adj EPS ⓘ | 7.9 | 6.4 | 8 | 10.4 | 2.6 | -1 | -1.6 | -2.4 | -1.2 | -0.8 | -1.2 |
| YoY Gr. | - | -18.2% | 23.9% | 29.7% | -75% | -138.2% | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 40.1 | 45.1 | 53 | 62.8 | 29.1 | 28.1 | 26.4 | 30.2 | 39.1 | 38.8 | 37.9 |
| Adj Net Profit ⓘ | 109 | 89 | 110 | 143 | 35.7 | -13.6 | -22.3 | -38.5 | -25.4 | -16.4 | -27 |
| Cash Flow from Ops. ⓘ | 143 | 89.8 | 147 | 105 | -12 | -45.2 | -36.7 | -36.6 | -22.9 | -20.6 | - |
| Debt/CF from Ops. ⓘ | 0.8 | 0.9 | 0.5 | 0.3 | -0.2 | -0 | -0 | -0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -34.4% | -47.2% | -4.6% | -13.7% | ||||
| Adj EPS ⓘ | -177% | -178.1% | NA | NA | ||||
| BVPSⓘ | -0.4% | 5.9% | 13.7% | -1% | ||||
| Share Price | -4.5% | -15.3% | 9.6% | 38% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 26.4 | 15.1 | 16.3 | 17.9 | 5.6 | -3.5 | -5.7 | -8.8 | -3.8 | -1.9 | -3.2 |
| Op. Profit Mgn % ⓘ | 30.7 | 26 | 30.6 | 37.8 | 18.2 | -243.3 | -222.9 | -304.6 | -201.7 | -263.3 | -473.2 |
| Net Profit Mgn % ⓘ | 20.9 | 17.8 | 20.3 | 22.9 | 12.5 | -94.5 | -165.8 | -325.3 | -187.2 | -139.9 | -316.4 |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 153 | 183 | 191 | 193 | 357 | 5,193 | 5,219 | 4,006 | 4,382 | 3,617 | 3,896 |
| Cash Conv. Cycle ⓘ | 50 | 56 | 56 | 57 | 81 | 12 | 21 | 31 | 13 | 29 | 3,777 |
No data to display
Return on Equity is Poor
Sales growth has been subdued in last 3 years -4.64%
Sales growth is not so good in last 4 quarters at -29.14%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -1.2 | -6.7 |
| TTM Sales (₹ Cr.) | 8.4 | 8.4 |
| BVPS (₹.) ⓘ | 37.9 | 8.8 |
| Reserves (₹ Cr.) ⓘ | 805 | 171 |
| P/BV ⓘ | 3.19 | 13.67 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 75.95 / 169.00 |
| All Time Low / High (₹) | 0.55 / 311.92 |
| Market Cap (₹ Cr.) | 2,634 |
| Equity (₹ Cr.) | 21.8 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 521 | 500 | 544 | 625 | 286 | 14 | 13 | 12 | 14 | 12 |
| Operating Expenses ⓘ | 361 | 370 | 378 | 389 | 234 | 50 | 44 | 48 | 41 | 43 |
| Manufacturing Costs | 124 | 141 | 151 | 146 | 106 | 28 | 25 | 25 | 21 | 21 |
| Material Costs | 178 | 163 | 147 | 152 | 69 | 0 | 0 | 0 | 0 | 0 |
| Employee Cost | 32 | 36 | 51 | 59 | 34 | 15 | 15 | 17 | 16 | 17 |
| Other Costs ⓘ | 28 | 31 | 29 | 32 | 25 | 8 | 3 | 6 | 5 | 5 |
| Operating Profit ⓘ | 159 | 130 | 165 | 236 | 52 | -35 | -30 | -37 | -28 | -31 |
| Operating Profit Margin (%) | 30.6% | 25.9% | 30.4% | 37.8% | 18.2% | -244.0% | -225.0% | -308.0% | -204.0% | -263.0% |
| Other Income ⓘ | 9 | 20 | 21 | 23 | 27 | 14 | 8 | 2 | 8 | 21 |
| Interest ⓘ | 5 | 6 | 6 | 5 | 2 | 1 | 1 | 1 | 0 | 0 |
| Depreciation ⓘ | 12 | 17 | 21 | 25 | 14 | 4 | 4 | 4 | 7 | 7 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 7 |
| Profit Before Tax ⓘ | 152 | 126 | 159 | 230 | 63 | -26 | -28 | -36 | -20 | -9 |
| Tax ⓘ | 43 | 26 | 36 | 72 | 24 | -12 | -5 | 0 | 0 | -1 |
| Profit After Tax | 109 | 100 | 123 | 158 | 39 | -14 | -23 | -36 | -20 | -8 |
| PAT Margin (%) | 20.9% | 20.0% | 22.7% | 25.3% | 13.7% | -95.4% | -167.0% | -306.0% | -148.0% | -68.5% |
| Adjusted EPS (₹) | 7.9 | 7.3 | 8.9 | 11.5 | 2.8 | -1.0 | -1.6 | -2.3 | -0.9 | -0.4 |
| Dividend Payout Ratio (%) | 7% | 25% | 10% | 12% | 49% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 559 | 623 | 732 | 867 | 402 | 388 | 365 | 476 | 853 | 845 |
| Share Capital ⓘ | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 15 | 22 | 22 |
| Reserves ⓘ | 547 | 611 | 719 | 854 | 389 | 375 | 352 | 461 | 832 | 824 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 90 | 66 | 56 | 33 | 2 | 1 | 0 | 0 | 0 | 0 |
| Long Term Debt | 61 | 42 | 26 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Short Term Debt | 28 | 24 | 30 | 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Payables | 44 | 36 | 38 | 57 | 7 | 6 | 3 | 2 | 2 | 2 |
| Others Liabilities ⓘ | 80 | 144 | 138 | 162 | 146 | 109 | 141 | 102 | 99 | 4 |
| Total Liabilities ⓘ | 773 | 869 | 964 | 1,119 | 557 | 503 | 509 | 580 | 954 | 851 |
Fixed Assets | ||||||||||
| Gross Block | 291 | 325 | 349 | 376 | 39 | 77 | 67 | 83 | 88 | 78 |
| Accumulated Depreciation | 119 | 20 | 43 | 68 | 17 | 52 | 46 | 46 | 51 | 50 |
| Net Fixed Assetsⓘ | 172 | 305 | 306 | 308 | 22 | 25 | 21 | 38 | 37 | 28 |
| CWIP ⓘ | 107 | 7 | 10 | 25 | 0 | 0 | 5 | 4 | 0 | 0 |
| Investmentsⓘ | 0 | 23 | 366 | 381 | 359 | 242 | 295 | 426 | 528 | 653 |
| Inventories | 82 | 83 | 93 | 139 | 0 | 0 | 0 | 0 | 0 | 1 |
| Trade Receivables | 40 | 54 | 46 | 62 | 3 | 2 | 2 | 1 | 1 | 1 |
Cash Equivalents  ⓘ
| 280 | 241 | 5 | 21 | 0 | 1 | 39 | 3 | 174 | 153 |
| Others Assetsⓘ | 92 | 155 | 139 | 183 | 172 | 233 | 148 | 109 | 214 | 15 |
| Total Assets ⓘ | 773 | 869 | 964 | 1,119 | 557 | 503 | 509 | 580 | 954 | 851 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 143 | 90 | 147 | 105 | -12 | -45 | -37 | -37 | -23 | -21 |
| PBT ⓘ | 152 | 126 | 159 | 230 | 63 | -26 | -28 | -36 | -20 | -9 |
| Adjustment ⓘ | 21 | 11 | 13 | 10 | -5 | -9 | -3 | -1 | -8 | -22 |
| Changes in Working Capital ⓘ | 8 | -20 | 10 | -92 | -55 | -7 | -5 | 1 | 6 | 5 |
| Tax Paid ⓘ | -38 | -27 | -35 | -44 | -15 | -3 | -1 | -1 | -1 | 6 |
| Cash Flow From Investing Activity ⓘ | -110 | -62 | -353 | -38 | 3 | 42 | 2 | -107 | -349 | -1 |
| Capex | -118 | -58 | -31 | -42 | -39 | -2 | -6 | -20 | -3 | 2 |
| Net Investments | 0 | -23 | -343 | 3 | 42 | 117 | -53 | -130 | -104 | 78 |
| Others ⓘ | 8 | 19 | 21 | 1 | 0 | -73 | 62 | 43 | -242 | -81 |
| Cash Flow From Financing Activityⓘ | 179 | -68 | -30 | -52 | 5 | 4 | 35 | 146 | 396 | -1 |
| Net Proceeds from Shares ⓘ | 200 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 397 | 0 |
| Net Proceeds from Borrowing ⓘ | 18 | -18 | 0 | -25 | 1 | -1 | -1 | -1 | 0 | 0 |
| Interest Paid ⓘ | -5 | -6 | -6 | -5 | -2 | -1 | -1 | 0 | 0 | 0 |
| Dividend Paid ⓘ | -34 | -25 | -13 | -19 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | -19 | -12 | -4 | 6 | 5 | 36 | 147 | -1 | -1 |
| Net Cash Flow ⓘ | 212 | -40 | -236 | 15 | -4 | 1 | 1 | 2 | 24 | -22 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 26.56 | 16.99 | 18.22 | 19.83 | 6.18 | -3.48 | -6.02 | -8.62 | -3.03 | -0.94 |
| ROCE (%) | 30.7 | 19.24 | 21.88 | 27.58 | 9.98 | -6.4 | -6.82 | -8.1 | -2.97 | -1.03 |
| Asset Turnover Ratio | 0.83 | 0.61 | 0.59 | 0.6 | 0.34 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 |
| PAT to CFO Conversion(x) | 1.31 | 0.9 | 1.2 | 0.66 | -0.31 | N/A | N/A | N/A | N/A | N/A | Working Capital Days |
| Receivable Days | 37 | 34 | 33 | 31 | 41 | 62 | 55 | 47 | 28 | 33 |
| Inventory Days | 56 | 60 | 59 | 68 | 0 | 0 | 4 | 3 | 0 | 22 |
| Payable Days | 87 | 89 | 91 | 114 | 170 | 0 | 0 | 0 | 0 | 0 |
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Shares are listed at Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange(HSE). It has a state of the art R&D center recognized by Department of Scientific & Industrial Research (DSIR), Ministry of Science and Technology, Government of India. Also, it has world class manufacturing facilities in the business of Pharmaceuticals and Fine Chemical Intermediates for Global Life Science Companies for New Chemical Entities (NCE's).
Business Units
C.R.A.M.S
The company’s main thrust is in Contract Research and Manufacturing Services (C-R-A-M-S). Suven's ‘C-R-A-M-S’ is in existence since 1991 serving as many as 22 global Life Science and Fine Chemical Companies by developing and supplying cost effective Pharmaceutical and Agro Chemical Intermediates for New Chemical Entities (NCE's) meeting world standards of Quality, Speed and Respect for Environment.
DDDSS
Drug Discovery & Development Support Services (DDDSS) aims to provide Contract Drug Discovery & Development services in Medicinal chemistry, Process chemistry, Analytical chemistry, In-vitroScreening, DMPK, Brain Microdialysis, CV Safety, In-vivo Metabolic Disorders & CNS Pharmacology, Phase-I Bio-analysis and Discovery Toxicology.
Suven Nishtaa Pharma
Suven Nishtaa Pharma (Suven Nishtaa), a joint venture company of Suven Life Sciences, is a Pharmaceutical Formulations Contract Services provider.
Suven Nishtaa, a 100% Export Oriented Unit, is engaged in providing end-to-end Drug Product Development services, viz.
Products
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
